XML 233 R62.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Segment information and revenue from contracts with customers - Additional information (Details)
€ in Thousands
12 Months Ended
Dec. 31, 2023
EUR (€)
customer
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Segment information and revenue from contracts with customers        
Equity and debt financing costs € 0 € 2,161 € 0  
Share issue related cost   450 0  
Property, plant and equipment 5,643 6,808 9,464  
Right-of-use assets 13,635 15,351 18,904 € 22,120
Provision for expected credit losses on contract assets 26 10 483  
Advance consideration included in contract liabilities 694 651 2,506  
Pharmaceutical Partner | Recognized over time.        
Segment information and revenue from contracts with customers        
Advance consideration included in contract liabilities 464      
-United States        
Segment information and revenue from contracts with customers        
Property, plant and equipment 14 76 147  
Right-of-use assets 0 0 137  
Share-Based Payment Arrangement, Nonemployee | SGAs | 2019 Plan        
Segment information and revenue from contracts with customers        
Costs capitalized 202      
Pharmaceutical        
Segment information and revenue from contracts with customers        
Setup Upfront Fees € 256 € 566 € 455  
Pharmaceutical | Pharmaceutical Partner        
Segment information and revenue from contracts with customers        
Number of customers | customer 1      
Percentage of revenue 12.60% 15.50% 24.80%  
Revenues recognized for contract liabilities € 372 € 1,951 € 3,201  
Diagnostics        
Segment information and revenue from contracts with customers        
Percentage of revenue 70.00% 66.00% 63.00%  
Diagnostics | Major diagnostic partner        
Segment information and revenue from contracts with customers        
Percentage of revenue 20.00%